Hepatocellular Carcinoma in a Chronic Hepatitis B Patient With Suppressed Viral Replication

KUTLU M., SAYIN KUTLU S., Dunya-Erdal A., Agladioglu K.

KLIMIK JOURNAL, vol.29, no.3, pp.130-132, 2016 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 29 Issue: 3
  • Publication Date: 2016
  • Doi Number: 10.5152/kd.2016.31
  • Journal Name: KLIMIK JOURNAL
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.130-132
  • Keywords: Hepatitis B virus, hepatocellular carcinoma, telbivudine, VIRUS INFECTION, RISK, THERAPY, ENTECAVIR
  • Dokuz Eylül University Affiliated: Yes


Suppressing viral replication is the main intervention for prevention of hepatocellular carcinoma (HCC) development, which is one of the purposes of treatment of chronic hepatitis B. We report a case of HCC in a 73-year-old woman with chronic hepatitis B who was treated and whose viral replication was successfully suppressed with antiviral therapy. The patient had anti-HBe positivity and her viral load was 1.01x10(6) IU/mL. Telbivudine treatment led to a decrease of HBV DNA below the detection limit on the second month of the treatment. But her a-fetoprotein level increased (121 ng/L) on the 30th month of the treatment. Magnetic resonance imaging showed a mass compatible with HCC on the liver and a biopsy revealed HCC. She was treated with chemo-embolization. Although viral suppression is achieved in patients with chronic hepatitis B, follow-up and HCC screening should be done regularly in patients who have HCC risk factors such as thrombocytopenia and older age, as in this case.